Humacyte's (HUMA) "Buy" Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA - Free Report) in a report issued on Monday,Benzinga reports. The brokerage currently has a $25.00 target price on the stock.

Several other equities research analysts also recently issued reports on HUMA. Benchmark lifted their price target on shares of Humacyte from $15.00 to $17.00 and gave the stock a "buy" rating in a research note on Monday, December 23rd. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price target (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 target price on shares of Humacyte in a research report on Friday, September 20th. BTIG Research reiterated a "buy" rating and set a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. Finally, Piper Sandler set a $6.00 target price on shares of Humacyte and gave the company a "neutral" rating in a research note on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Humacyte presently has an average rating of "Buy" and an average price target of $13.71.

Humacyte Trading Down 4.8 %

Shares of NASDAQ HUMA traded down $0.22 during midday trading on Monday, hitting $4.39. The stock had a trading volume of 2,862,357 shares, compared to its average volume of 3,626,862. The company has a market capitalization of $552.52 million, a price-to-earnings ratio of -3.28 and a beta of 1.32. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. Humacyte has a 1-year low of $2.48 and a 1-year high of $9.97. The company has a fifty day moving average price of $4.67 and a 200 day moving average price of $5.69.

Insider Activity

In other news, CEO Laura E. Niklason sold 811,172 shares of the business's stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the sale, the chief executive officer now directly owns 2,419,712 shares in the company, valued at approximately $10,743,521.28. The trade was a 25.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of the firm's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares of the company's stock, valued at $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,500,000 shares of company stock worth $6,606,799 in the last 90 days. Company insiders own 11.20% of the company's stock.

Institutional Investors Weigh In On Humacyte

Large investors have recently modified their holdings of the stock. Private Advisor Group LLC boosted its stake in Humacyte by 1.8% in the third quarter. Private Advisor Group LLC now owns 373,110 shares of the company's stock worth $2,030,000 after purchasing an additional 6,510 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Humacyte by 32.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company's stock worth $168,000 after buying an additional 8,557 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Humacyte by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company's stock valued at $125,000 after acquiring an additional 8,965 shares in the last quarter. Brookstone Capital Management acquired a new position in shares of Humacyte during the fourth quarter worth approximately $56,000. Finally, XTX Topco Ltd increased its holdings in shares of Humacyte by 48.8% in the third quarter. XTX Topco Ltd now owns 34,049 shares of the company's stock valued at $185,000 after purchasing an additional 11,172 shares in the last quarter. 44.71% of the stock is currently owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.